Abstract
The ongoing need for diverse therapeutic and diagnostic tools against SARS-CoV-2 has led to the exploration of aptamers as "chemical antibodies." This study identifies nCoV-S1-Apt1, a DNA aptamer with sub-nanomolar affinity ($K_D \approx 0.118$ nM) for the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein. Through rapid CE-SELEX screening and multi-stage characterization, nCoV-S1-Apt1 was shown to effectively block the interaction between the viral RBD and the human ACE2 receptor. Neutralization assays using spike-pseudotyped viruses confirmed dose-dependent inhibition of viral entry, highlighting the aptamer's potential for both rapid diagnostics and COVID-19 therapeutics.
Introduction
While vaccines remain the cornerstone of COVID-19 prevention, the medical community requires stable, cost-effective therapeutic and diagnostic alternatives to traditional antibodies. Monoclonal antibodies, though effective, face challenges regarding production costs, temperature sensitivity, and batch-to-batch variability. Aptamers—short, single-stranded oligonucleotides that fold into specific 3D structures—offer a promising solution. They possess antibody-like binding specificity but are more stable, easier to synthesize chemically, and exhibit lower immunogenicity. This research focuses on identifying a DNA aptamer capable of targeting the SARS-CoV-2 spike protein (S1 subunit) to prevent viral entry into host cells.
Methods
The researchers utilized Capillary Electrophoresis-based Systematic Evolution of Ligands by Exponential Enrichment (CE-SELEX) to rapidly isolate high-affinity sequences. Unlike traditional SELEX methods, CE-SELEX leverages high separation efficiency to identify binders in significantly fewer rounds. The screening process included positive selection against the S1 protein, negative selection against non-target proteins, and complex background screening in human serum to ensure high specificity.
Binding kinetics and affinities were characterized using Surface Plasmon Resonance (SPR) and Capillary Zone Electrophoresis (CZE). Molecular docking simulations (PyMOL) were employed to visualize the aptamer-protein interface. Finally, the neutralization potential was evaluated using a SARS-CoV-2 spike-pseudotyped virus model, measuring infection levels via green fluorescent protein (GFP) expression and luciferase activity.
Results and Discussion
The screening process identified several candidates, with nCoV-S1-Apt1 emerging as the lead sequence. It exhibited an exceptional binding affinity ($K_D$) of approximately 0.118 ± 0.033 nM. Interestingly, the aptamer showed higher affinity for the full S1 subunit compared to the isolated RBD, suggesting a "kinetic advantage" provided by the larger protein scaffold.
Specificity tests demonstrated that nCoV-S1-Apt1 does not cross-react with common serum proteins such as human serum albumin (HSA) or IgG. In competitive ELISA assays, the aptamer inhibited the RBD-ACE2 interaction with an $IC_{50}$ of 80.12 nM. Molecular docking indicated that Apt1 binds to residues 45–71 of the S1 protein, a region that directly overlaps with the ACE2 binding site.
Functional neutralization was confirmed in cell culture experiments. Treatment with nCoV-S1-Apt1 resulted in a dose-dependent reduction of pseudovirus infection, as evidenced by decreased luciferase activity and GFP fluorescence in confocal microscopy. Additionally, the aptamer was successfully integrated into a gold nanoparticle (AuNP) colorimetric assay, enabling visual detection of the S1 protein in human serum with a limit of ~3.125 nM.
Conclusion and Future Directions
This study successfully identified a high-affinity DNA aptamer capable of neutralizing SARS-CoV-2 entry by blocking the RBD-ACE2 interface. While these results are promising, the study's reliance on pseudovirus models necessitates further validation using authentic live SARS-CoV-2 strains and emerging variants. Future work will focus on in vivo safety and efficacy trials in animal models and the development of integrated point-of-care diagnostic platforms.
Summary updated